Prof Sharma talks to ecancertv at ECC 2015 about the targeted drug nivolumab, and how it significantly prolongs survival in patients with advanced kidney cancer, whose disease has progressed after their first treatment.
In the interview she highlights the findings of the CheckMate 025 trial, an open-label, phase III trial that compared the PD-1 checkpoint inhibitor nivolumab against everolimus in previously treated patients with metastatic renal cell carcinoma (mRCC). Based on the results of this trial, the US Food and Drug Administration granted nivolumab a breakthrough therapy designation for mRCC.
Prof Sharma also comments on the potential for using nivolumab in combination with other targeted anticancer agents, such as ipilimumab.
